justthenews2d
Social media censorship of COVID vaccine injury discussion led to suicides, families, advocates say
"The suicides are a result of not knowing there is support, not being able to reach out for help to access the support that ...
Janus Henderson Global Life Sciences Fund Q4 2024 Commentary
The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV
KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, ...
Choreo LLC Boosts Stake in argenx SE (NASDAQ:ARGX)
Choreo LLC lifted its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange ...
Investing3d
CSL reports $2 billion profit for H1 FY2025 but needs a stronger second half
“CSL delivered a solid result for the first half of the 2025 financial year led by CSL Behring. Strong demand for many of our market-leading therapies has translated into sales growth, particularly in ...
H.C. Wainwright maintains Buy on Immunovant, $51 price target
H.C. Wainwright reaffirmed their Buy rating on Immunovant (NASDAQ:IMVT) shares with a price target of $51.00, aligning with the broader Wall Street sentiment. According to InvestingPro data, analyst ...
Guggenheim cuts Immunovant stock target to $44, maintains Buy
Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...